SINGAPORE and LONDON, Jan 12 (Bernama-GLOBE NEWSWIRE) —Claritas HealthTech Pte. Ltd. (“Claritas”), a healthcare technology company specializing in innovative deep-learning and advanced image enhancement to improve the quality and efficiency of medical imaging and AI assisted diagnosis, announces today it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market Claritas iPET™. Claritas iPET is an image processing software that implements a powerful algorithm-based solution to enhance the quality of PET scans by denoising, sharpening organ boundaries and achieving super-resolution. PET scans can be further improved to provide additional details by using an overlay of an MRI or CT image of the same region. The iPET enhancement capability is significant as it can reduce scan times by up to 80% while yielding similar image quality as captured under standard duration.
“While Claritas iPET enhances PET scans captured under standard duration and provides improved visibility of details previously obscured by noise, the degree of enhancement is particularly significant for reduced duration scans and scans using reduced contrast agent,” said Dr. Laszlo Neumann, Head of Research and Development, at Claritas HealthTech. He added, “We are very pleased to receive the FDA 510(k) clearance for Claritas iPET as the software can be used to enhance PET and PET-CT/MRI scans and substantially reduce scan duration times improving patient experience and increasing hospital and imaging centre efficiency.”
